Saturday, October 10, 2015 2:26:41 PM
Firstly, I greatly appreciate your candor. There is a lot that I agree with you about. I agree that board changes need to be made. I don't know if that is something that needs to be changed now, or around efficacy. The real rubber that meets the road in ability to make a deal will definitely be anticipated at the end of this trial. So, having someone now that can make a deal without any real data other than safety is something I'm not certain about myself. I see other companies making deals, which definitely raises an eyebrow, especially milestone deals prior to any efficacy...so it is fraud rating that that hasn't happened yet.
Many have different views about the IPO being a good or a bad thing. I persoNlky am not sure why they didn't wait until some efficacy was demonstrated. Perhaps an overreaction to a pull back on biotech...? I honestly don't know. Perhaps it was an attempt to gather funds with minimal dilution. I don't know. However, I am not naive enough to assent to what you are saying. So I am watching the company actions and trial very closely. I may even pull out some funds after efficacy, simply because there should be a bump, and that would be a great time to hedge my funds.
I think I'll email Dr Mark Kay, but I wonder what exactly is the issue he finds with the vector. Is is transduction? Because there is a lot of preclinical that shows this doesn't seem to be a problem unless there is some other info you can share. Is it immune response in those that have antibodies already? Well, we haven't actually tested it on those people yet. Additionally, it has been stated that a short course of Corticosteroids would be a simple way to manage any response. Is it shrna expression? Benitec has released that all patients have shown shrna expression in those that have been dosed.
In regards to efficacy, if you listen to the audio, he clearly says, "programs". So I'm wondering if he is just referring to an overall point where a good sense of where Benitec is going will be seen. I personally don't believe he is referring only to the TT-034 trial.
Tribetarna surely is on a lot of shareholders minds, including mine. I hope that some sense can be made, and questions will be raised by shareholders regarding this. I personally want to know why this hit a brick wall. I also believe that remuneration of employees needs to be reigned in until better progress can be made. I feel that holding management accountable this way is not unreasonable.
Like I said, I am keenly aware of both sides, and will voice my concerns in my personal posts as they come, but your points are well taken. I hope the worst is over, and that efficacy or other major news, brings some relief to shareholders. Thanks for your post, and keep this board informed of anything you catch. I know that I would personally appreciate it!
Many have different views about the IPO being a good or a bad thing. I persoNlky am not sure why they didn't wait until some efficacy was demonstrated. Perhaps an overreaction to a pull back on biotech...? I honestly don't know. Perhaps it was an attempt to gather funds with minimal dilution. I don't know. However, I am not naive enough to assent to what you are saying. So I am watching the company actions and trial very closely. I may even pull out some funds after efficacy, simply because there should be a bump, and that would be a great time to hedge my funds.
I think I'll email Dr Mark Kay, but I wonder what exactly is the issue he finds with the vector. Is is transduction? Because there is a lot of preclinical that shows this doesn't seem to be a problem unless there is some other info you can share. Is it immune response in those that have antibodies already? Well, we haven't actually tested it on those people yet. Additionally, it has been stated that a short course of Corticosteroids would be a simple way to manage any response. Is it shrna expression? Benitec has released that all patients have shown shrna expression in those that have been dosed.
In regards to efficacy, if you listen to the audio, he clearly says, "programs". So I'm wondering if he is just referring to an overall point where a good sense of where Benitec is going will be seen. I personally don't believe he is referring only to the TT-034 trial.
Tribetarna surely is on a lot of shareholders minds, including mine. I hope that some sense can be made, and questions will be raised by shareholders regarding this. I personally want to know why this hit a brick wall. I also believe that remuneration of employees needs to be reigned in until better progress can be made. I feel that holding management accountable this way is not unreasonable.
Like I said, I am keenly aware of both sides, and will voice my concerns in my personal posts as they come, but your points are well taken. I hope the worst is over, and that efficacy or other major news, brings some relief to shareholders. Thanks for your post, and keep this board informed of anything you catch. I know that I would personally appreciate it!
All my posts, comments, and investments are not to be considered investment advice in any way.
Recent BNTC News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 12:10:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 12:09:20 PM
- Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 05/14/2026 12:00:00 PM
- Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting • GlobeNewswire Inc. • 04/28/2026 11:00:00 AM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 03/20/2026 08:03:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2026 01:09:54 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2026 01:07:48 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/11/2026 05:15:29 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/30/2026 09:02:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/03/2025 09:19:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/02/2025 10:27:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2025 10:37:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2025 10:36:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/20/2025 10:35:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:31:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 10:05:33 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 11/12/2025 11:06:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2025 02:29:10 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/07/2025 02:26:08 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/05/2025 10:17:07 PM
- Benitec Biopharma Shares Surge 20% After FDA Grants Fast Track Status for OPMD Gene Therapy • IH Market News • 11/03/2025 02:35:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2025 12:11:20 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/14/2025 09:00:08 PM
